- Sanofi/Regeneron have reported results in a phase 3 trial evaluating use of dupilumab in treatment of moderate-to-severe eczema. Adding dupilumab to standard-of-care treatment (topical corticosteroids-TCAs) significantly improved outcomes, the trial concluded.
- Dupilumab selectively targets interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins, which are implicated in various immune-mediated diseases and possibly other atopic and allergic diseases.
- Analysts are looking for up to $2.5 billion in peak sales for dupilumab.
Dupilumab received breakthrough designation for the eczema indication (it is also in late-stage development for moderate to severe asthma) in November 2014. This is the third data set from this clinical program, which updates and reinforces positive 16-week data.
In the 52-week analysis, 40% of patients treated with dupilumab (300 mg weekly) in addition to TCAs experienced a complete, or near complete clearing of their skin, compared with 12.5% of patients treated only with TCAs. Likewise, 64% of patients who received dupilumab plus TCAs had the severity of their eczema reduced by 75% or more.